Sign inJoin waitlistJoin the waitlist

Michael DiGiovanna

Chair, Breast Cancer Tumor Board · Yale Cancer Center

Credentials: · · · ·

History

Breast Cancer Tumor Board Department · Yale Cancer Center
Present
Breast Cancer Tumor Board · Yale-New Haven Hospital
Present
Office of Education · Yale-New Haven Hospital
Present

Yale University
Yale Univ Sch of Med
1990–1994
Yale University
1993–1994
Yale University
1988–1990
Cornell University, Biology (Biochemistry), Music
1980–1984
Cornell University
1981–1984

Research

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
New England Journal of Medicine · 2019 · 2,052 citations
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Journal of Clinical Oncology · 2020 · 452 citations
Impact of financial burden of cancer on survivors' quality of life
Journal of Oncology Practice · 2014 · 389 citations

Lajos Pusztai
16 papers
Maysa Abu-Khalaf
15 papers
Gina Chung
13 papers
DL
Donald Lannin
12 papers
EH
Erin Hofstatter
12 papers
Tara Sanft
12 papers
Sarah Schellhorn
10 papers · 4 as a fellow
AS
Andrea Silber
9 papers
AC
Anees Chagpar
9 papers
BK
Brigid Killelea
9 papers
NH
Nina Horowitz
7 papers
Bruce Haffty
6 papers

Clinical trials

Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer
Study chair · Completed · Phase 2
Yale University
1994–2000
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
Site PI · Recruiting · Phase 2
GlaxoSmithKline
2026–2027
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Site PI · Recruiting · Phase 3
Greenwich LifeSciences, Inc.
2022–2031